Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Eupraxia Pharmaceuticals reported advances in its clinical trials and financial results for the third quarter of 2024, including positive data from their RESOLVE and SPRINGBOARD trials. The company also secured C$44.5 million in funding and strengthened its management team, despite a net loss of $6.0 million.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
